Dan V. Iosifescu, MD

Department of Psychiatry, NYU Grossman School of Medicine, New York, New York; Nathan Kline Institute, Orangeburg, New York

  • 17Articles
  • 163.2KReads
  • 2004–2026Active
  • 104Collaborators
  • 630Citations

About

Dan V. Iosifescu, MD, is affiliated with the Department of Psychiatry at NYU Grossman School of Medicine and the Nathan Kline Institute. Since 2004, Dr. Iosifescu has published extensively on topics including major depressive disorder, bipolar disorder, anxiety, neurology, and psychopharmacology. His work encompasses clinical trials and meta-analyses investigating antidepressant treatments, augmentation strategies, and biomarkers for treatment response. Frequent collaborators include Maurizio Fava, George I. Papakostas, and Andrew A. Nierenberg.

Publications

JCP
When Do Physical Symptoms After Antidepressant Cessation Reflect Pharmacodynamic versus Non-pharmacodynamic Clinical Phenomena?
ASCP Corner

When Do Physical Symptoms After Antidepressant Cessation Reflect Pharmacodynamic versus Non-pharmacodynamic Clinical Phenomena?

August 6, 2026

Focuses on descriptive symptom phenomenology and strategies to minimize discomfort during antidepressant cessation, with possible explanations for unusual, delayed, or protracted symptoms in patients for whom non-pharmacodynamic features may...
, , , et al
JCP
Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life
Original Research

Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life

August 11, 2025

Augmentation with aripiprazole, but not rTMS, improved quality of life significantly versus venlafaxine XR/duloxetine switch in patients with treatment-resistant depression.
, , , et al
JCP
Rapidity of Improvement With Intranasal Esketamine for MDD
Meta-Analysis

Rapidity of Improvement With Intranasal Esketamine for MDD

December 12, 2022

This meta-analysis found that augmenting antidepressants with intranasal esketamine vs placebo was more effective in reducing depression severity at 24 hours and study endpoint.
, , , et al
JCP
Effect of Benzodiazepines on Antidepressant Effects of Ketamine
Original Research

Effect of Benzodiazepines on Antidepressant Effects of Ketamine

November 14, 2022

Findings of studies examining the impact of benzodiazepines on antidepressant effects of ketamine are contradictory. This study assessed whether concomitant oral benzodiazepines differentially affected treatment response to ketamine versus...
, , , et al
JCP
Very Low-Level Transcranial Photobiomodulation for MDD
Original Research

Very Low-Level Transcranial Photobiomodulation for MDD

August 8, 2022

Transcranial photobiomodulation may be efficacious for major depressive disorder, but the optimal dose is not known. Here, a very low dose was studied to establish a threshold for lack...
, , , et al
JCP
Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in MDD
Original Research

Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in MDD

May 30, 2022

Altered glutamatergic neurotransmission has been implicated in the pathogenesis of depression. This phase 3 trial evaluated the efficacy and safety of AXS-05 (dextromethorphan-bupropion) in the treatment of major depressive...
, , , et al
JCP
ASCP Corner

Wrestling With Antidepressant Use in Bipolar Disorder

January 19, 2021

The question of whether, and when, antidepressants are appropriate in bipolar disorder is a hotly debated topic. This ASCP Corner article summarizes the key concepts with greatest relevance for...
, ,
JCP
Meta-Analysis

Esketamine Augmentation in Major Depressive Disorder

May 26, 2020

The FDA has now approved intranasal esketamine as augmention in treatment-resistant depression, and recent studies of its efficacy have been encouraging. This meta-analysis synthesizes the evidence to provide an...
, , , et al
JCP
Commentary

Maintaining the Initial Clinical Response After Ketamine in Bipolar and Unipolar Depression: An Important Next-Step Challenge

June 24, 2015

JCP
Original Research

Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression

September 2, 2014

, , , et al
JCP
Original Research

A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Augmentation in Treatment-Resistant Major Depressive Disorder

July 15, 2013

, , , et al
JCP
Original Research

Quantitative Electroencephalogram Biomarkers for Predicting Likelihood and Speed of Achieving Sustained Remission in Major Depression: A Report From the Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD) Trial

January 15, 2013

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe